ACCESS Newswire
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
📈
AI Sentiment
Highly Positive
8/10
- Home
- APVO
as of 12-12-2025 3:41pm EST
$1.12
$0.04
-3.88%
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Chart Type:
Time Range:
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 21.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -19.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $298.00 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered APVO Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 76.35%
76.35%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Aptevo Therapeutics Inc. (APVO)
Grant Grady III
Buy
Director
APVO Nov 10, 2025
Avg Cost/Share
$1.49
Shares
13,513
Total Value
$20,134.37
Owned After
13,514
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Grant Grady III | APVO | Director | Nov 10, 2025 | Buy | $1.49 | 13,513 | $20,134.37 | 13,514 |
Latest Aptevo Therapeutics Inc. News
APVO Breaking Stock News: Dive into APVO Ticker-Specific Updates for Smart Investing
Compare APVO vs Leading Stocks
See how APVO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "APVO Aptevo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.